HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
about
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulationThe many facets of the Wilms' tumour gene, WT1The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.Pathway-based analysis of breast cancer.WT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo.HER2 phosphorylates and destabilizes pro-apoptotic PUMA, leading to antagonized apoptosis in cancer cellsOverexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemiaWilms' tumor gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line.Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese populationWilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repressionpH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy.BP1 transcriptionally activates bcl-2 and inhibits TNFalpha-induced cell death in MCF7 breast cancer cellsKi67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patientsA genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patientsA human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activityErbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers.Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.The density of microvessels positive for Wilms' tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas.Tumor Vaccines for Malignant Gliomas.Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation.An Integrating Approach for Genome-Wide Screening of MicroRNA Polymorphisms Mediated Drug Response Alterations.Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma.The CUG-translated WT1, not AUG-WT1, is an oncogene.A Zbtb7a proto-oncogene as a novel target for miR-125a.WT1 protein is cleaved by caspase-3 in apoptotic leukemic cells.
P2860
Q21195216-BD2A5ABB-6728-46AE-AF37-831A713D25C9Q28264516-E652C8F3-DD77-41A3-87D0-390A10328DBBQ33723383-352EB951-3FA6-41B9-A023-B7D7DA55C7A2Q33758011-5149AA43-FA8B-495D-90DC-35C5ABF4E11CQ34924201-C76F94E1-2250-4FCC-8410-855946FB4663Q35043596-39A4A40B-1241-4E80-BCA8-AFE70EA1CA3FQ35130976-F0336859-6651-4005-BB59-5641B6CAC78DQ35489149-5704F179-8A06-4C50-9C83-AC6CB3AF87A5Q35666497-F84F1319-9E5E-424C-B628-E48DD2274E5BQ35751162-5B7F2159-85F6-4B7B-BC0E-32186180E460Q36058740-866F3EE9-4D75-4350-B9F1-2C7A3C7A0064Q36458739-21FFAEEE-D699-475D-962D-877D9A7F4F1AQ36709515-3FE0099E-2104-4485-B493-A98E88145588Q36782669-E81A97AD-8CEF-4CD1-B42F-4D5B5CFEE31CQ36844361-B453BA10-1F85-453E-ADD2-3FA4A18A8F00Q37197414-31C1817C-3640-4E15-B82A-DE24133927A2Q37400824-877338ED-E69E-4A02-9D34-0A54BDCFD801Q37675627-E0C2497E-89F9-4F92-93C7-F76AEA16B285Q37721627-E8F656B8-F095-432B-9488-E229B225CF24Q38935396-CA3DD437-9CE2-4A21-91A7-25F40E874CEAQ39028953-C2078FA2-3CA9-4F0A-AFC0-18EB66621D0EQ39228039-7FB0AB89-7414-44ED-9C9B-09C17FCF055AQ40087603-7D9AE64D-190A-48DD-8D1F-3072C4838EB0Q40114088-A1194F57-D4E0-4CCF-BFF4-D505D9D05050Q42291062-BCFFD496-F30B-4BAD-BA51-4CBCE76A632AQ44584782-640085E3-7FC7-44F6-AF86-FFA5FE38EE46Q47639653-9D258F70-62F0-44E0-8E69-A16E968507E4Q49085598-E5FA6272-0EE6-42EC-8DDA-7A6617D56611Q51064660-77CFFB9F-2694-4BB1-93C5-D2CDC9BEF8B0
P2860
HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
HER2/neu increases the express ...... ptosis in breast cancer cells.
@en
type
label
HER2/neu increases the express ...... ptosis in breast cancer cells.
@en
prefLabel
HER2/neu increases the express ...... ptosis in breast cancer cells.
@en
P2860
P356
P1433
P1476
HER2/neu increases the express ...... optosis in breast cancer cells
@en
P2093
Ana M Tari
Musaffe Tuna
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208345
P407
P577
2005-02-01T00:00:00Z
P5875
P6179
1051200087